Progyny Inc PGNY

$36.18 -0.40 (-1.09%)

Valuation

Market cap
2,664,549,000
Revenue TTM
$1,288,660,000
Net income TTM
$58,520,000
P/E (trailing)
33.87
P/E (forward)
25.94
Profit margin
4.54%
Debt to equity
0.00

Trading

Volume
869,500
Avg volume
1,136,366
Day's range
$36.08 – $36.76
Shares out
73,647,000
Stochastic %K
88%
Beta
0.97
Analysts
Strong Buy
Price target
$36.42

Price

Company profile

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integr...

Show more

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Industry
Healthcare Plans
Sector
Healthcare
Phone
212 888 3124
Website
https://www.progyny.com
Address
1359 Broadway, New York, United States

Latest news

Stocktwits

MarkNewtonCMT Nov 10, 1:01 AM
Progyny- Last weeks' high-volume push above July '26 peaks was helpful towards allowing this rally to push even higher following the successful consolidation in $PGNY above the area of its breakout this past Summer Longer-term downtrend from 2021 has been exceeded & this joins a number of Medical Services stocks which have begun to claw back in recent months. While this has some work to do before reaching all-time highs, it's the structural improvement in a former laggard as part of a very bullish sector that has my attention #IBDPartner IBD stocks from @Marketsurge @IBDinvestors
0 replies
GTA_Terminal Nov 8, 12:11 PM
Dark pool check on $PGNY: what traded off the exchanges in the latest session. Price barely moved (+1.4%), which is what you'd expect if somebody big is building or unwinding a position quietly. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PGNY&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PGNY Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-activity-unusual-off-exchange-trading-in-progyny-pgny?utm_source=stocktwits&utm_medium=social
0 replies
Doozio Nov 5, 9:02 PM
$PGNY it’s a baby bull!
0 replies
stockcat420 Nov 5, 3:19 PM
$PGNY yeah baby
1 replies
EarningsInsider Nov 4, 10:46 PM
https://www.marketbeat.com/earnings/reports/2026-11-4-progyny-inc-stock/ $PGNY Progyny Earnings Transcript
0 replies
BullMeetsWorld Nov 4, 9:51 PM
$PGNY welp, here we are
0 replies
StocktwitsEarnings Nov 4, 9:42 PM
$PGNY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.52 up 15.56% YoY • Reported revenue of $341.25M up 8.90% YoY • Progyny raised the midpoint of Full Year 2026 guidance: revenue is projected at $1.37B to $1.39B, net income at $107M to $110.6M, and Adjusted EBITDA at $235M to $240M.
0 replies
wannabePGNYanalyst Nov 4, 9:21 PM
$PGNY Pretty uneventful quarter in terms of the key metrics. Profit margin was down from 25.5% to 24.5%. Cash and cash equivalents were down from $152.632 million to $116.82 million while outstanding shares count only decreased 1.2% due to the buybacks. The best news lately is the successful selling season coupled with near 100% retention.
0 replies